Wafergen Reports Eight-Fold Increase in Q3 Revenues as Net Loss Swells | GenomeWeb

WaferGen Biosystems reported today an approximately eight-fold increase in revenues, but said that net loss swelled by more than 70 percent in the third quarter of 2010, the first full quarter of commercial availability for the company's flagship real-time PCR system.

Revenue for the quarter ended Sept. 30 grew to $633,000 from $79,000 for Q3 2009. Meantime, revenue for the first nine months of 2010 grew to $1.5 million compared to $190,000 in the same three quarters last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.